Literature DB >> 11501779

Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer.

K Yüce1, C Baykal, C Genç, A Al, A Ayhan.   

Abstract

OBJECTIVE: The aim of this study was to investigate the peritoneal fluid and serum lactate dehydrogenase (LDH) levels in patients with ovarian masses. MATERIALS &
METHODS: Peritoneal fluid and serum lactate dehydrogenase (LDH) levels were measured in 27 patients with epithelial ovarian carcinoma and 38 with benign ovarian tumors. Serum and peritoneal fluid LDH levels were also compared with the levels of CA-125.
RESULTS: Both of the marker levels in ovarian cancer patients were significantly higher than those in patients with benign ovarian tumors. Serous and undifferantiated carcinomas presented higher marker levels than endometrioid and mucinous carcinomas. High grade, advanced stage and positive cytology were associated with higher serum and peritoneal fluid LDH levels; there was an inefficient correlation between them but, when these two markers were used together with CA-125, sensitivity of CA-125 increased to 70%.
CONCLUSIONS: In conclusion, serum LDH can be used to discriminate adnexal mass origin and peritoneal fluid LDH may have prognostic value because of the strict relationship with advanced stage, poor histologic type, higher grade and positive abdominal cytology. Peritoneal LDH is found to be a reliable biochemical marker related to prognosis in ovarian carcinoma patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11501779

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  6 in total

1.  Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia.

Authors:  Umran Kucukgoz Gulec; Semra Paydas; Ahmet Baris Guzel; Selim Buyukkurt; Gulsah Seydaoglu; Mehmet Ali Vardar
Journal:  Med Oncol       Date:  2012-01-25       Impact factor: 3.064

2.  Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.

Authors:  M Scartozzi; R Giampieri; E Maccaroni; M Del Prete; L Faloppi; M Bianconi; E Galizia; C Loretelli; L Belvederesi; A Bittoni; S Cascinu
Journal:  Br J Cancer       Date:  2012-02-07       Impact factor: 7.640

3.  Post-treatment serum lactic dehydrogenase as a predictive indicator for distant metastasis and survival of patients with nasopharyngeal carcinoma.

Authors:  Jin Wang; Li Li; Bai-Qiang Dong; Yu-Jin Xu; Yuan-da Zheng; Zhong-Wen Sun; Yang Yang; Yuan-Yuan Chen; Xiao-Zhong Chen; Ming Chen
Journal:  Oncotarget       Date:  2016-05-10

4.  Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis.

Authors:  M I Koukourakis; A Giatromanolaki; E Sivridis; G Bougioukas; V Didilis; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

5.  JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer.

Authors:  Haifeng Qiu; Amanda L Jackson; Joshua E Kilgore; Yan Zhong; Leo Li-Ying Chan; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Oncotarget       Date:  2015-03-30

6.  Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy.

Authors:  Michael Kyriakides; Nona Rama; Jasmin Sidhu; Hani Gabra; Hector C Keun; Mona El-Bahrawy
Journal:  Oncotarget       Date:  2016-02-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.